Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCN-03
- Development stage
- Preclinical
- Lead developer
- Theriva Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
VCN-03 is an oncolytic adenovirus-mediated therapy being developed for the treatment of cancer. It is designed to selectively infect and replicate within tumor cells, causing direct lysis and promoting immune-mediated antitumor effects. The mechanism is presumed to be similar to other VCN oncolytic viruses, which have stroma-degrading properties and enhance both direct cytolytic activity in cancer cells and immune cell infiltration into tumors. Developed initially by VCN Biosciences, a subsidiary of Synthetic Biologics, VCN-03 represents an advanced candidate in the oncolytic virus therapy pipeline, but specific molecular or payload details beyond its class as oncolytic adenovirus are not publicly disclosed[13][16].
- Brand names
- VCN-03VCN03VCN 03
- Other names
- VCN-03VCN03VCN 03
02
Targets
αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)CXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on VCN-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCN-03.